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nd/4.0/).Chronic lymphocytic leukemia (CLL) is considered more
common in Western countries, and its incidence is believed
to decrease moving east across the globe. Therefore, the
prevalence of monoclonal B-cell lymphocytosis (MBL), a
pre-CLL condition, is also expected to be less common in
non-Western countries. MBL [1] is characterized by the pres-
ence of <5000  109/L circulating clonal B cells that can be
CD5+ or CD5. In Western countries, MBL prevalence as
detected by flow cytometry varies from 0.6% to 14% in
healthy individuals >40 years of age, dependent upon thelevel of sensitivity and number of parameters applied. Using
four- to six-color flow cytometry, most studies report a
prevalence of 5% in the Western population, with the
CLL phenotype about five-fold more prevalent than the
non-CLL phenotype. It is important to distinguish this entity
from overt CLL as the elderly population expands and flow-
cytometric immunophenotyping increasingly provides
higher levels of detection. More individuals are incidentally
found to have MBL [2]. A review of the current literature
indicated that, although most cases of CLL are preceded
by MBL, only 1–2% may progress to CLL requiring therapy
[3]. The epidemiologic and genetic factors associated with
MBL contributing to progression to CLL are not properly
identified. MBL also carries an identical frequency of cyto-hocytosis
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2 M. Aljurf et al.genetic abnormalities as that observed in CLL, but it has yet
to be defined whether any subgroup can predict progression
to CLL [3,4]. MBL has been classified as MBL with a CLL-like
phenotype, MBL with an atypical CLL phenotype, and MBL
with a non-CLL phenotype [5]; however, MBL incidence
and relative proportions of CLL phenotype versus non-CLL
phenotype have not been adequately studied in non-Wes-
tern countries. We investigated the prevalence and pheno-
type of MBL in a population sample in the Middle East
(King Faisal Specialist Hospital & Research Center, Riyadh,
Saudi Arabia). The study was approved by the institution
office of research affairs.
Individuals (365) mostly consisting of Saudi Arabian
nationals and a smaller number of individuals from neigh-
boring countries and >50 years of age were studied. Addi-
tionally, these patients exhibited normal peripheral blood
counts and no evidence of hematologic disease. Peripheral
blood samples were immunophenotyped by eight-color flow
cytometry to detect CD45, CD19, CD20, CD5, CD10, CD3,
and kappa and lambda light chains based on acquiring 1
million cells each.
Monoclonal B cells were detected in 21 (6%) individuals
(14 male, 7 female; median age: 70 years; range: 64–91).
However, only 10 of these cases (48%) displayed the typical
CD19+/CD5+ CLL phenotype. Two cases (9.5%) displayed
CD5 clonal B cells, and two cases (9.5%) displayed CD10+
clonal B-cells. The remaining seven cases (33%) showed a
concomitant CD5+ and a CD10+ clonal population, both
expressing the same light chain. While we cannot be certain
that these CD5+ and CD10+ cell populations represent the
same or different clones, the finding that the two popula-
tions in all seven cases showed the same light-chain restric-
tion supports that the two populations represented the
same clone.Please cite this article in press as: Aljurf M et al., Prevalence and relative
phenotypes in the Middle Eastern population, Hematol Oncol Stem CellIn conclusion, MBL in the Middle Eastern region observed
in this study was as common as that reported in Western
countries. Compared with Western countries, however, it
is the non-CLL phenotype which was more prevalent here,
comprising 52% of our MBL group, with most of these cases
showing cells expressing CD5 and CD10. The exact classifica-
tion of these cases is difficult, and it appears likely that they
represent marginal-zone phenotypes; however, the possibil-
ity of a coexisting follicular-lymphoma clone cannot be
excluded. Pure follicular-lymphoma phenotypes are
observed in 10% of our MBL cases. Further studies with long
follow-up are needed.
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